Chemotherapy for the brain: The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease

Journal of Neuroscience

Volumn 24, Issue 46, 2004, Pages 10335-10342

  Ferrante, Robert J ^a,b   Ryu, Hoon ^a,b   Kubilus, James K ^a,b   D'Mello, Santosh ^c   Sugars, Katharine L ^d   Lee, Junghee ^a,b   Lu, Peiyuan ^e   Smith, Karen ^a,b   Browne, Susan ^g   Beal, M Flint ^g   Kristal, Bruce S ^g,h   Stavrovskaya, Irina G ^g,h   Hewett, Sandra ⁱ   Rubinsztein, David C ^d   Langley, Brett ^e   Ratan, Rajiv R ^e,f,g,h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h BURKE MEDICAL RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

HD; Histone methylation; Htt; Huntingtin; Huntington's disease; Mithramycin; Neuroprotection; Transcription

Indexed keywords

GLUTAMATE RECEPTOR; HISTONE H3; MITHRAMYCIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; GENE SILENCING; HISTOPATHOLOGY; HUNTINGTON CHOREA; MALE; MOTOR PERFORMANCE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METHYLATION; RAT; SURVIVAL TIME; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BRAIN; CELLS, CULTURED; GENE SILENCING; HUMANS; HUNTINGTON DISEASE; LYSINE; MALE; METHYLATION; MICE; MICE, TRANSGENIC; MITOCHONDRIA, LIVER; MOTOR ACTIVITY; N-METHYLASPARTATE; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PLICAMYCIN; RATS; RATS, INBRED BN; RATS, INBRED F344; RECEPTORS, GLUTAMATE; TRANSCRIPTION, GENETIC;

EID: 20844455450     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2599-04.2004     Document Type: Article

References (33)

1. Albin R, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42:733-738.
2. Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative disease? Ann Neurol 31:119-130.
3. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181-4192.
4. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92:7105-7109.
5. Cha JH (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23:387-392.
6. Chatterjee S, Zaman K, Ryu H, Conforto A, Ratan RR (2001) Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol 49:345-354.
7. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13:1407-1420.
8. Coles R, Caswell R, Rubinsztein DC (1998) Functional analysis of the Huntington's disease (HD) gene promoter. Hum Mol Genet 7:791-800.
9. Coqueret O, Berube G, Nepveu A (1998) The mammalian Cut homeodomain protein functions as a cell-cycle-dependent transcriptional repressor which down modulates p21WAF1/CIP1/SDI1 in S phase. EMBO J 17:4680-4694.
10. D'Mello SR, Galli C, Ciotti T, Calissano P (1993) Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc Natl Acad Sci USA 90:10989-10993.
11. Dufort D, Nepveu A (1994) The human cut homeodomain protein represses transcription from the c-myc promoter. Mol Cell Biol 14:4251-4257.
12. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296:2238-2243.
13. el-Hodiri HM, Perry M (1995) Interaction of the CCAAT displacement protein with shared regulatory elements required for transcription of paired histone genes. Mol Cell Biol 15:3587-3596.
14. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22:1592-1599.
15. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23:9418-9427.
16. Freiman RN, Tjian R (2002) Neurodegeneration. A glutamine-rich trail leads to transcfiption factors. Science 296:2149-2150.
17. Hake SB, Xiao A, Allis CD (2004) Linking the epigenetic "language" of covalent histone modifications to cancer. Br J Cancer 90:761-769.
18. Jones Jr DE, Cui DM, Miller DM (1995) Expression of beta-galactosidase under the control of the human c-myc promoter in transgenic mice is inhibited by mithramycin. Oncogene 10:2323-2330.
19. Kristal BS, Brown AM (1999) Apoptogenic ganglioside GD3 directly induces the mitochondrial permeability transition. J Biol Chem 274:23169-23175.
20. Li S, Moy L, Pittman N, Shue G, Aufiero B, Neufeld EJ, LeLeiko NS, Walsh MJ (1999) Transcriptional repression of the cystic fibrosis transmembrane conductance regulator gene, mediated by CCAAT displacement protein/cut homolog, is associated with histone deacetylation. J Biol Chem 274:7803-7815.
21. Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H, Li XJ (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22:1277-1287.
22. Nishio H, Walsh MJ (2004) CCAAT displacement protein/cut homolog recruits G9a histone lysine methyltransferase to repress transcription. Proc Natl Acad Sci USA 101:11257-11262.
23. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5:731-736.
24. Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, Shinkai Y, Allis CD (2003) Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell 12:1591-1598.
25. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R, Ratan RR (2003a) Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci 23:3597-3606.
26. Ryu H, Lee J, Olofsson BA, Mwidau A, Deodoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, Ratan RR (2003b) Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci USA 100:4281-4286.
27. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler Jr JF, Greenamyre JT, Snyder SH, Ross CA (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5:1194-1198.
28. Skalnik DG, Strauss EC, Orkin SH (1991) CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter. J Biol Chem 266:16736-16744.
29. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743.
30. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, Woodard EJ, Snyder EY, Eichler ME, Friedlander RM (2004) Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 101:3071-3076.
31. Uliasz TF, Hewett SJ (2000) A microtiter trypan blue absorbance assay for the quantitative determination of excitotoxic neuronal injury in cell culture. J Neurosci Methods 100:157-163.
32. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 100:10483-10487.
33. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu du C, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417:74-78.